The diagnostic and therapeutic management of leptomeningeal carcinomatosis

Annals of Oncology

Volumn 15, Issue SUPPL. 4, 2004, Pages

  Pavlidis, N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTARABINE; CYTOSTATIC AGENT; FOLINIC ACID; GEMCITABINE; HYDROCORTISONE; LETROZOLE; METHOTREXATE; TAMOXIFEN; THIOTEPA; TRASTUZUMAB;

ANAMNESIS; ARACHNOIDITIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CARCINOMATOUS MENINGITIS; CEREBROSPINAL FLUID EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; HEADACHE; HUMAN; LEPTOMENINX; LEUKOENCEPHALOPATHY; LUNG NON SMALL CELL CANCER; MENINGITIS; MENTAL DISEASE; MOTOR DYSFUNCTION; MYELOGRAPHY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; SEIZURE; SENSITIVITY AND SPECIFICITY; SENSORY DYSFUNCTION; SYSTEMIC THERAPY; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CEREBROSPINAL FLUID; DIAGNOSIS, DIFFERENTIAL; HUMANS; INCIDENCE; INJECTIONS, SPINAL; MENINGEAL NEOPLASMS;

EID: 9744250912     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh941     Document Type: Article

References (89)

1. Jayson GC, Howell A. Carcinomatous meningitis in solid tumours. Ann Oncol 1996; 7: 773-786.
2. Grossman SA, Krabak US. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999; 25: 103-109.
3. Eberth CJ. Zur Entwicklung des Epitheliomas (Cholesteatomas) dur Pia under der Lungs. Virchow's Arch 1870; 49: 51-63.
4. Shapiro WR, Posner JB, Yukitaka Y et al. Treatment of meningeal neoplasms. Cancer Treat Rep 1977; 61: 733-743.
5. Nugent JC, Bunn PA Jr, Mathews MJ et al. CNS metastases in small cell bronchogenic carcinoma: increasing frequently and changing pattern with lengthening survival. Cancer 1979; 44: 1885-1893.
6. Bleyer WA. Leptomenoningeal cancer in leukemia and solid tumours. Curr Probl Cancer 1988; 12: 185-237.
7. Liaw C, Ng K, Huang J et al. Meningeal carcinomatosis from solid tumours: clinical analysis of 42 cases. J Formosan Med Assoc 1992; 91: 299-303.
8. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumours: experience with 90 patients. Cancer 1982; 49: 759-772.
9. Yap HY, Yap BS, Tashima CK et al. Meningeal carcinomatosis from breast cancer. Cancer 1978; 42: 283-286.
10. Boogerd W, Hart AAM, van der Sande JJ et al. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 1991; 67: 1685-1695.
11. Jayson GC, Howell A, Harris M et al. Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer 1994; 74: 3135-3141.
12. Aroney RS, Dalley DN, Chan WK et al. Meningeal carcinomatosis in small cell carcinoma of the lung. Am J Med 1981; 71: 26-32.
13. Rosen ST, Aisner J, Makuch RW et al. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathological review of the National Cancer Institute experience. Medicine (Baltimore) 1982; 61: 45-53.
14. Balducci L, Little DD, Khansur T et al. Carcinomatous meningitis in small cell lung cancer. Am J Med Sci 1984; 287: 31-33.
15. Amer MH, Al Sarraf M, Baker LH et al. Malignant melanoma and central nervous system metastases. Cancer 1978; 42: 660-668.
16. Redman BG, Tapazoglou E, Al Sarraf M. Meningeal carcinomatosis in head and neck cancer. Report of six cases and review of the literature. Cancer 1986; 58: 2656-2661.
17. Aboulafia DM, Taylor LP, Crane RD et al. Carcinomatous meningitis complicating cervical cancer: a clinicopathologic study and literature review. Gynecol Oncol 1996; 60: 313-318.
18. Gordon AN, Kavanagh JJ, Wharton JT et al. Successful treatment of leptomeningeal relapse of epithelial ovarian cancer. Gynecol Oncol 1984; 18: 119-124.
19. Crino PB, Sater RA, Sperling M et al. Renal cell carcinomatous meningitis: pathologic and immunohistochemical features. Neurology 1995; 45: 189-191.
20. Mandell S, Wernz J, Morales P et al. Carcinomatous meningitis from transitional cell carcinoma of bladder. Urology 1985; 25: 250-251.
21. Bishop JR, Moul JW, Maldonado L et al. Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, docorubicin and cisplatin) chemotherapy. Urology 1990; 36: 373-377.
22. Bunn PA, Schein PS, Banks PM. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. Blood 1976; 47: 3-10.
23. Recht LD. Neurologic complications of sytemic lymphoma. Neurol Clin 1991; 9: 1001-1015.
24. Walker RW. Neurologic complications of leukemia. Neurol Clin 1991; 9: 989-999.
25. Nicolson GL, Kawaguchi T, Kawaguchi M et al. Brain surface invasion and metastasis of murine malignant melanoma variants. J Neurooncol 1987; 4: 209-218.
26. Gonzalez-Vitale JC, Garcia-Bunnel R. Meningeal carcinomatosis. Cancer 1976; 37: 2906-2911.
27. Hayat G, Ehsan T, Selhorst JB et al. Magnetic resonance evidence of peri-neural metastasis. J Neuroimag 1995; 5: 122-125.
28. Azzarelli B, Mirkin LD, Goheen M. The leptomeningeal vein A site of re-entry of leukemia cells into the systemic circulation. Cancer 1984; 54: 1333-1343.
29. Boyle R, Thomas M, Adams JH. Diffuse involvement of the leptomeninges by tumor - a clinical and pathological study of 63 cases. Postgrad Med 1980; 56: 149-158.
30. Kokkoris CP. Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid? Cancer 1983; 51: 154-160.
31. Norris LK, Grossman SA, Olivi A. Neoplastic meningitis following surgical resection of isolated cerebellar metastases: a potentially preventable complication. J Neurooncol 1997; 32: 215-223.
32. Hildebrand J, Aoun M. Chronic meningitis: still a diagnostic challenge. J Neurol 2003; 250: 653-660.
33. DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998; 38: 245-252.
34. Chamberlain MC. Carcinomatous meningitis. Arch Neurol 1997; 54: 16-17.
35. Balm M, Hammack J. Leptomeningeal carcinomatosis. Arch Neurol 1996; 53: 626-632.
36. Hitchins RN, Bell DR, Woods RL et al. A prospective randomized trial of single agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987; 5: 1655-1662.
37. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995; 38: 51-57.
38. Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer. Arch Neurol 1974; 30: 122-137.
39. Theodore WH, Gendelman S. Meningeal carcinomatosis. Arch Neurol 1981; 38: 696-699.
40. Grossman SA, Finkelstein DM, Ruckdeschel DL et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 1993; 11: 561-569.
41. Chamberlain MC. Comparative spine imaging in leptomeningeal metastases. J Neurooncol 1995; 29: 233-238.
42. Kaplan JG, DeSouza TG, Farkash A et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumours, lymphomas, and leukemias. J Neurooncol 1990; 9: 225-229.
43. Reuler JB, Meier D. Leptomeningeal carcinomatosis with normal CSF features. Arch Intern Med 1979; 139: 237-238.
44. Twijnstra A, Ongerboer de Visser BW, van Zanten AP. Diagnosis of leptomeningeal metastasis. Clm Neurol Neurosurg. 1987; 89: 79-85.
45. Glass JP, Melamed M, Chernik NL et al. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979; 29: 1369-1375.
46. Chamberlain MC. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology 1998; 50: 1173-1175.
47. Schold SC, Wasserstrom WR, Fleischer M et al. Cerebrospinal fluid biochemical markers of central nervous system metastasis. Ann Neurol 1980; 97: 604-610.
48. Wasserstrom WR, Schwarz MK, Fleisher M et al. Cerebrospinal fluid biochemical markers in central nervous system tumours: a review. Ann Clin Lab Sci 1981; 11: 239-251.
49. Klee GG, Tallman RD, Goelliner JR et al. Elevation of carcino-embryonic antigen in cerebrospinal fluid among patients with meningeal carcinomatosis. Mayo Clin Proc 1986; 61: 9-13.
50. Shuttleworth E, Allen N. CSF beta-glucuronidase assay in the diagnosis of neoplastic meningitis. Arch Neurol 1980; 37: 684-687.
51. Twijnstra A, van Zanten AP, Nooven WJ et al. Sensitivity and specificity of single and combined tumour markers in the diagnosis of leptomeningeal metastasis from breast cancer. J Neurol Neurosurg Psychiatry 1986; 49: 1246-1250.
52. Twijnstza A, van Zanten AP, Hart AA et al. Serial lumbar and ventricle cerebrospinal fluid dehydrogenase activities in patients with leptomeningeal metastases from solid and haematological tumours. J Neurol Neurosurg Psychiatry 1987; 50: 313-320.
53. Van Zanten AP, Twijnstra A, Ongerboer de Visser BW et al. Tumour markers in the cerebrospinal fluid of patients with central nervous system metastases from extracranial malignancies. Clin Chim Acta 1988; 175: 157-166.
54. Fleisher M, Wasserstrom WR, Schold SC et al. Lactic dehydrogenase isoenzymes in the cerebrospinal fluid of patients with systemic cancer. Cancer 1981; 47: 2654-2659.
55. Adachi N. Beta-2-microglobulin levels in the cerebrospinal fluid, their value as a disease marker. Eur Neurol 1991; 31: 181-185.
56. Lampl Y, Paniri V, Eshel Y et al. Alkaline phosphatase level in CSF in various brain tumours and pulmonary carcinomatous meningitis. J Neurooncol 1990; 9: 35-40.
57. Bach F, Soletormas G, Dombernowsky P. Tissue polypeptide antigen activity in cerebrospinal fluid: a marker of central nervous system metastases of breast cancer. J Natl Cancer Inst 1991; 83: 779-784.
58. Nakagawa H, Kubo S, Murasawa A et al. Measurements of CSF biochemical tumour markers in patients with meningeal carcinomatosis and brain tumours. J Neurooncol 1992; 12: 111-120.
59. Bach F, Bach F, Pedersen AG et al. Creatinine kinase-BB in the cerebrospinal fluid as a marker of CNS metastases and leptomeningeal carcinomatosis in patients with breast cancer. Eur J Clin Oncol 1989; 25: 1703-1709.
60. Siegal T, Ovadia H, Yatsiv I et al. CSF myelin basic protein levels in leptomeningeal metastases. Relationship to disease activity. J Neurol Sci 1987; 78: 165-173.
61. Nagai A, Terashima M, Harada T et al. Cathepsin B and H activities and cystatin C concentrations in cerebrospinal. fluid from patients with leptomeningeal metastasis. Clin Chim Acta 2003; 329: 53-60.
62. Moseley RP, Oge K, Shafgat S et al. HMFG1 antigen: a new marker for carcinomatous meningitis. Int J Cancer 1989; 44: 440-444.
63. Stockhammer G, Poewe W, Burgstaller S et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 2000; 54: 1670-1676.
64. Chamberlain MC, Kormanik PA, Glantz MJ. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastasis. Neurooncol 2001; 3: 42-45.
65. Castro MP, McDonald TJ, Qualman SJ et al. Cerebrospinal fluid gastrin releasing peptide in the diagnosis leptomeningeal metastases from small cell carcinoma. Cancer 2001; 91: 2122-2126.
66. Sze G, Soletsky S, Bronen R et al. MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. Am J Nucl Radiol 1989; 10: 965-975.
67. Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: a comparison of gadolinium enhanced MR and contrast enhanced CT of the brain. Neurology 1990; 40: 435-438.
68. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995; 38: 51-57.
69. Krol G, Sze G, Malkin NM et al. MR of cranial and spinal meningeal carcinomatosis: comparison with CT and myelography. Am J Roentgenol 1988; 151: 583-588.
70. Komori T, Delbeke D. Leptomeningeal carcinomatosis and intramedullary spinal cord metastases from lung cancer: detection with FDG position emission tomography. Clin Nucl Med 2001; 26: 905-907.
71. Blaney SM, Balis FM, Poplack DG. Pharmacologic approach to the treatment of meningeal malignancy. Oncology 1991; 5: 107-116.
72. Galicich JH, Guido LJ. Ommaya device in carcinomatous and leukemic meningitis. Surg Clin N Am 1974; 54: 915-922.
73. Lishner M, Perrin RG, Feld R et al. Complications associated with Ommaya reservoirs in patients with cancer. Arch Int Med 1990; 150: 173-176.
74. Machado M, Salcman M, Kaplan RS et al. Expanded role of the cerebrospinal fluid reservoir in neurooncology: indications, causes of revision and complications. Neurosurgery 1985; 17: 600-603.
75. Sculier JP. Treatment of meningeal carcinomatosis. Cancer Treat Rev 1985; 12: 95-104.
76. Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973; 289: 770-773.
77. Bleyer WA. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 1981; 65: 89-98.
78. Fulton DS, Levin VA, Gutin PH et al. Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumours and systemic tumours. Cancer Chemother Pharmacol 1982; 8: 285-291.
79. Slevin ML, Piall EN, Aherne GW et al. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside on plasma and cerebrospinal fluid. J Clin Oncol 1983; 9: 546-551.
80. Dae-Young K, Keun-Wook L, Tak Y et al. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol 2003; 33: 608-612.
81. Pfeffer MR, Wygoda M, Siegal T. Leptomeningeal metastases - treatment results in 98 consecutive patients. Isr J Med Sci 1988; 24: 611-618.
82. Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994; 44: 1463-1469.
83. Yap H, Yap B, Rasmussen S et al. Treatment for meningeal carcinomatosis on breast cancer. Cancer 1982; 49: 219-222.
84. Chen YM, Chen MC, Tsai CM, Perng RP. Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis - a case report. Lung Cancer 2003; 40: 99-101.
85. Laufman LR, Forsthoefel KF. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2001; 2: 235.
86. Ozdogan MO, Samur M, Bozcuk HS et al. Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. Jpn J Clin Oncol 2003; 33: 229-231.
87. Chamberlain MC. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2001; 56: 216-217.
88. Boogerd W, Dorresteijn LD, van Der Sande JJ et al. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2000; 12: 117-119.
89. Mencel PJ, DeAngelis LM, Motzer RJ. Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. Cancer 1994; 73: 1892-1894.